Abstract:Relaxin-3 (also known as INSL7) is a recently identified neuropeptide belonging to the insulin/relaxin superfamily. It has putative roles in the regulation of stress responses, food intake, and reproduction by activation of its cognate G-protein-coupled receptor RXFP3. It also binds and activates the relaxin family peptide receptors RXFP1 and RXFP4 in vitro. To obtain a europium-labeled relaxin-3 as tracer for studying the interaction of these receptors with various ligands, in the present work we propose a novel site-specific labeling strategy for the recombinant human relaxin-3 that has been previously prepared in our laboratory. First, the N-terminal 6 × His-tag of the single-chain relaxin-3 precursor was removed by Aeromonas aminopeptidase and all of the primary amines of the resultant peptide were reversibly blocked by citroconic anhydride. Second, the A-chain N-terminus of the blocked peptide was released by endoproteinase Asp-N cleavage that removed the linker peptide between the B- and A-chains. Third, an alkyne moiety was introduced to the newly released A-chain N-terminus by reaction with the highly active primary amine-specific N-hydroxysuccinimide ester. Fourth, after removal of the reversible blockage under mild acidic condition, europium-loaded DOTA with an azide moiety was introduced to the two-chain relaxin-3 carrying the alkyne moiety through click chemistry. Using this site-specific labeling strategy, homogeneous monoeuropium-labeled human relaxin-3 could be obtained with good overall yield. In contrast, conventional random labeling resulted in a complex mixture that was poorly resolved because human relaxin-3 has four primary amine moieties that all react with the modification reagent. Both saturation and competition binding assays demonstrated that the DOTA/Eu(3+)-labeled relaxin-3 retained high binding affinity for human RXFP3, RXFP4, and RXFP1 and was therefore a suitable non-radioactive and stable tracer to study the interaction of various natural or designed ligands with these receptors. Using this site-specific labeling strategy, other functional probes, such as fluorescent dyes, biotin, or nanoparticles could also be introduced to the A-chain N-terminal of the recombinant human relaxin-3. Additionally, we improved the time-resolved fluorescence assay for the DOTA-bound europium ion which paves the way for the use of DOTA as a lanthanide chelator for protein and peptide labeling in future studies.

Development of a Novel Ligand Binding Assay for Relaxin Family Peptide Receptor 3 and 4 Using NanoLuc Complementation

Development of a synthetic relaxin-3/INSL5 chimeric peptide ligand for NanoBiT complementation binding assays

A Novel BRET-based Binding Assay for Interaction Studies of Relaxin Family Peptide Receptor 3 with Its Ligands

Application of the novel bioluminescent ligand–receptor binding assay to relaxin-RXFP1 system for interaction studies

Exploring Electrostatic Interactions of Relaxin Family Peptide Receptor 3 and 4 with Ligands Using a NanoBiT-based Binding Assay

Hydrophobic Interactions of Relaxin Family Peptide Receptor 3 with Ligands Identified Using a NanoBiT-based Binding Assay

Rapid preparation of bioluminescent tracers for relaxin family peptides using sortase-catalysed ligation

Development of a Selective Agonist for Relaxin Family Peptide Receptor 3

Exploring Receptor Selectivity of the Chimeric Relaxin Family Peptide R3/I5 by Incorporating Unnatural Amino Acids.

A Novel Ultrasensitive Bioluminescent Receptor-Binding Assay of INSL3 Through Chemical Conjugation with Nanoluciferase.

Design, Recombinant Expression and Convenient A‐chain N‐terminal Europium‐labelling of a Fully Active Human Relaxin‐3 Analogue

Elucidation of relaxin-3 binding interactions in the extracellular loops of RXFP3

A Convenient Method for Europium‐labeling of a Recombinant Chimeric Relaxin Family Peptide R3/I5 for Receptor‐binding Assays

Quantitative Measurement of Cell Membrane Receptor Internalization by the Nanoluciferase Reporter: Using the G Protein-Coupled Receptor RXFP3 As a Model

Site-specific DOTA/europium-labeling of recombinant human relaxin-3 for receptor-ligand interaction studies

Using the novel HiBiT tag to label cell surface relaxin receptors for BRET proximity analysis

Distinct but overlapping binding sites of agonist and antagonist at the relaxin family peptide 3 (RXFP3) receptor

A Simple Approach for the Preparation of Mature Human Relaxin-3.

Design, Recombinant Preparation and Europium-Labeling of a Fully Active Easily-Labeled INSL3 Analog for Receptor-Binding Assays

Micromechanical measurement of membrane receptor binding for label-free drug discovery.

High-Throughput Screening Campaign Identified a Potential Small Molecule RXFP3/4 Agonist